These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 19351237)

  • 1. Bortezomib and Waldenstrom's macroglobulinemia.
    Pascal L; Gay J; Willekens C; Wemeau M; Balkaran S; Robu D; Roccaro A; Morel P; Ghobrial I; Leleu X
    Expert Opin Pharmacother; 2009 Apr; 10(5):909-16. PubMed ID: 19351237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Waldenström's macroglobulinemia].
    Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
    Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
    Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of proteasome inhibition in Waldenström's macroglobulinemia.
    Roccaro AM; Sacco A; Leleu X; Azab AK; Azab F; Runnels J; Jia X; Ngo HT; Melhem M; Moreau AS; Ghobrial IM
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):94-6. PubMed ID: 19362985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
    Treon SP; Hunter ZR; Matous J; Joyce RM; Mannion B; Advani R; Cook D; Songer J; Hill J; Kaden BR; Sharon D; Steiss R; Leleu X; Branagan AR; Badros A
    Clin Cancer Res; 2007 Jun; 13(11):3320-5. PubMed ID: 17545538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
    Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waldenström's macroglobulinemia and bortezomib.
    Leblond V
    Haematologica; 2005 Dec; 90(12):1589A. PubMed ID: 16330427
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel agents in the treatment of Waldenström's macroglobulinemia.
    Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
    Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Investig Drugs; 2017 Feb; 26(2):197-205. PubMed ID: 28043164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.
    Sacco A; Ghobrial IM; Roccaro AM
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1025-9. PubMed ID: 21933107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
    Laubach JP; Mitsiades CS; Roccaro AM; Ghobrial IM; Anderson KC; Richardson PG
    Leuk Lymphoma; 2009 May; 50(5):694-702. PubMed ID: 19452315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitor therapy for Waldenström's macroglobulinemia.
    Dimopoulos MA; Terpos E; Kastritis E
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):235-7. PubMed ID: 23562304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel biologically based therapies for Waldenstrom's macroglobulinemia.
    Mitsiades CS; Mitsiades N; Richardson PG; Treon SP; Anderson KC
    Semin Oncol; 2003 Apr; 30(2):309-12. PubMed ID: 12720159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future therapeutic approach for Waldenström's macroglobulinemia.
    Souchet-Cömpain L; Choquet S; Leblond V; Nguyen S
    Immunotherapy; 2014; 6(3):333-48. PubMed ID: 24762077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
    Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
    Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
    Mitsiades CS
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
    Treon SP; Tripsas C; Hanzis C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P; Turnbull B; Hunter ZR
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):433-7. PubMed ID: 23084402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waldenstrom macroglobulinemia.
    Leleu X; Roccaro AM; Moreau AS; Dupire S; Robu D; Gay J; Hatjiharissi E; Burwik N; Ghobrial IM
    Cancer Lett; 2008 Oct; 270(1):95-107. PubMed ID: 18555588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.